Ask about this productRelated genes to: PSMB9 Blocking Peptide
- Gene:
- PSMB9 NIH gene
- Name:
- proteasome subunit beta 9
- Previous symbol:
- LMP2
- Synonyms:
- RING12, beta1i, PSMB6i
- Chromosome:
- 6p21.32
- Locus Type:
- gene with protein product
- Date approved:
- 1991-12-18
- Date modifiied:
- 2016-10-05
Related products to: PSMB9 Blocking Peptide
Related articles to: PSMB9 Blocking Peptide
- Epigenetic modifications may illuminate mechanisms by which HIV and antiretroviral therapy (ART) exposure during critical developmental periods affect biological pathways and chronic comorbidity risk. We examined genome-wide DNA methylation (DNAm) in youth with perinatally-acquired HIV (YPHIV) compared to perinatally HIV-exposed uninfected youth (YPHEU) at two timepoints. In YPHIV, we assessed associations of HIV RNA viral load, CD4 count, and inflammation with DNAm alterations. - Source: PubMed
Publication date: 2026/06/05
Shiau StephanieBrummel Sean SHu JunjieDouglas JasmineZumpano FrancescaCorley MichaelJao JenniferPurswani MurliPatel KunjalMarsit Carmen J - Patients with lung cancer brain metastases can benefit from immune checkpoint inhibitors (ICI). However, intracranial responses are often limited and not always concordant with activity seen in extracranial disease. Defects in IFNγ signaling and HLA class-I antigen presentation machinery (APM) on malignant cells can drive immune evasion and ICI resistance, and have traditionally been viewed as interdependent. The possible role of these alterations in non-small cell lung cancer (NSCLC) brain progression remains poorly understood. - Source: PubMed
Publication date: 2026/05/28
Vilariño Noeliade Rodas Miguel LópezVillalba-Esparza MariaRajendran Barani KumarHuang BoyuHijazo-Pechero SaraCostantini AdrienRanjan KishuRamos-Paradas JavierLu Benjamin YNadal ErnestGoldberg Sarah BNguyen Don XSchalper Kurt A - Complex human diseases exhibit substantial clinical heterogeneity driven by poorly understood molecular mechanisms, while many also lack sufficient molecular and omics data for mechanistic investigation, hindering therapeutic development. We introduce PiMInfer, a phenotype-to-mechanism framework that leveraged largely available real-world clinical data-based deep phenotypic characterizations with a biomedical knowledge graph approach to resolve disease clinical heterogeneity into phenotype-informed molecular modules, thereby accelerating therapeutic target discovery. We applied PiMInfer to investigate Hidradenitis Suppurativa (HS), an autoimmune skin disease with poorly understood pathogenesis and limited treatment options. PiMInfer identified a coherent, phenotype-informed HS gene module (PiHSM) and functional endotypes, which were validated using multimodal evidence. In silico drug repurposing using PiHSM prioritized Carfilzomib, targeting the immunoproteasome subunit PSMB9, essential for MHC Class I antigen presentation. Preclinical testing using human patient lesional skin explants confirmed its anti-inflammatory activity and demonstrated a significant downregulation of IFN-γ, IL-17, and mTOR signaling pathways within HS lesional microenvironment through single-cell RNA sequencing. PiHSM-based network predictions further suggest a potential enhanced efficacy of combining Carfilzomib with approved HS agents. Collectively, PiMInfer provides a scalable framework that bridges real-world phenome-wide comorbid associations to mechanism-anchored therapeutic discovery, enabling a paradigm shift in precision medicine approaches for complex diseases with limited molecular characterization and in need of better therapeutic strategies. - Source: PubMed
Publication date: 2026/05/17
Wang Wei-TingZhou ManqiTong JieLin Meng-JuKe AlisonWei MeihanXu ZhenxingTai HansenParvathaneni AarthiHill Khyla TCohen Steven RPetukhova LynnChiu Ernest SWang FeiLu Catherine PSu Chang - Preterm birth (PTB, < 37 weeks of gestation) is a major public health concern in the United States, with Black women experiencing a higher incidence compared to White women. Although some studies have identified social, medical, and obstetric risk factors for PTB, the biological mechanisms underlying spontaneous PTB (sPTB) risk remain unclear. We conducted a secondary analysis using data from Black participants enrolled in the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b), (n = 1073) from 2010 to 2013. Peripheral whole blood samples were collected from all participants between 6 + 0/7 and 13 + 6/7 weeks of gestation. Demographic, behavioral and clinical data were gathered through surveys, and pregnancy outcomes were obtained through chart abstraction. We used the Infinium Methylation EPIC v2.0 BeadChip for epigenome-wide association (EWAS) of DNA methylation and sPTB. - Source: PubMed
Publication date: 2026/05/24
Zhao TingtingZhao YihongReho PaoloSamari GoleenWapner RonaldHazi ArielleWu HaotianBarcelona Veronica - Despite significant advances, the molecular basis and thus patient-tailored therapeutic options for inborn errors of immunity remain unknown in a significant number of patients. - Source: PubMed
Publication date: 2025/11/18
Fournier BenjaminPoirier LéaAbramowski VincentMerlin EtienneDeutsch HélèneBastard PaulCallebaut IsabellePicard CapucineRosain JérémieKüry SébastienBézieau StéphaneFabre MoniqueCastelle MartinNeven BénédicteMoshous Despinade Villartay Jean-PierreEbstein Frédéric